Press releases

Beactica nominated as “Technology Rising Star” by Deloitte

Beactica, the leading Swedish fragment-based drug discovery company spun out from Uppsala University announces that it is amongst 25 companies nominated as "Technology Rising Stars” by management consultants Deloitte. "We are delighted to be one of the 25 fastest growing new technology companies in Sweden” says... [...]

Beactica announces fragment-based drug discovery agreement

Uppsala, Sweden, April 27th, 2011 Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the agreement, Beactica will use its proprietary drug discovery... [...]

Beactica awarded €0.7 million from EU for pioneering influenza research

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has received a grant of up to €700 000 from the EU 7th Framework Programme to support the Company’s pioneering work in the area of influenza. In the FluCure project, Beactica will apply its proprietary fragment-based... [...]

Beactica announces the appointment of a new Chairman and a new Member to its Board

Uppsala, Sweden, December 14th, 2010 Beactica, the leading Swedish fragment-based drug discovery company, today announced that board member Gisela Sitbon will assume the position of Chairman and that Mr Jan Mellberg will join its Board, both effective immediately. Dr Gisela Sitbon has more than 25 years experience... [...]